When it comes to dieting, misconceptions can sometimes overshadow scientific advice. Some people think that losing weight ...
A weight-loss drug has been proven to also reduce the risk of a stroke or heart attack, according to a new trial. The makers of Wegovy, Novo Nordisk, say its latest study shows it cuts risk of a ...
From heart health to weight loss, coffee could have unexpected benefits Coffee may be one of the world's most popular drinks, but it has long been criticized for its harmful effects on sleep, stress ...
More recently, sibutramine and rimonabant were approved in Europe, then removed from the market because of cardiovascular ...
Discover how carbohydrates from whole grains, fruits, and nonstarchy vegetables can prevent middle-age weight gain. Learn ...
Semaglutide, the active ingredient in drugs like Wegovy and Ozempic, is also effective at reducing symptoms of heart failure, new research shows. A study published this month in the New England ...
Commissions we earn from partner links on this page do not affect our opinions or evaluations. Our editorial content is based on thorough research and guidance from the Forbes Health Advisory Board.
Weight-loss drugs such as Ozempic and Mounjaro cause some people to also lose the joy of eating. Is it worth it?
The benefits of the drug semaglutide, sold under the brand names Ozempic and Wegovy, seem to go beyond controlling diabetes and helping people shed pounds. New research shows that the drug also ...
What is the DASH Diet? Dietary Approaches to Stop Hypertension, or DASH, is a diet plan recommended for those who want to prevent or stop high blood pressure. It does this by increasing the intake ...
FEAR WEIGHT LOSS no longer. The science is in, and it doesn't take a crash diet, a juice cleanse, or anything else dramatic in order to lose weight. It's all about small changes in daily habit.
The products featured in this article have been independently reviewed. When you buy something through the retail links on this page, we may earn commission at no cost to you, the reader.
